U.S. markets closed

Astellas Pharma Inc. (ALPMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.21+0.06 (+0.40%)
At close: 03:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.15
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.15 - 15.25
52 Week Range14.21 - 18.18
Avg. Volume95,964
Market Cap27.95B
Beta (5Y Monthly)0.56
PE Ratio (TTM)30.42
EPS (TTM)0.50
Earnings DateN/A
Forward Dividend & Yield0.41 (2.72%)
Ex-Dividend DateMar 29, 2022
1y Target Est17.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALPMY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: KDDI CorporationKDDI is Japan's second-largest wireless operator (31% market share), the largest pay-TV operator (53% market share) and the second-largest provider of fibre-to-the-home broadband (12% market share). It has grown through acquisition and is focusing on increasing the number of customers who subscribe to more than one telecommunication service. It is also looking to grow its Life Design business which includes commerce, energy, and finance and had over 24.5 million IOT connections by the end of March 2022.
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
  • PR Newswire

    Astellas Announces Management Structure

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following changes to its management structure effective October 1, 2022.

  • Investor's Business Daily

    Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

    Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

  • Benzinga

    Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say

    Earlier today, Seagen Inc (NASDAQ: FBI) and Astellas Pharma Inc (OTC: ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev (enfortumab vedotin-ejfv) in metastatic urothelial carcinoma (mUC). Needham says that the results from Cohort K primarily live up to expectations. The management has previously indicated that results from Cohort K could be used to support accelerated approval in the 1L cis-ineligible mUC setting. See the Seagen Analyst Page here.